571 related articles for article (PubMed ID: 33193367)
1. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
Front Immunol; 2020; 11():575492. PubMed ID: 33193367
[TBL] [Abstract][Full Text] [Related]
2. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
3. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.
Hosseini E; Schwarer AP; Ghasemzadeh M
Iran J Allergy Asthma Immunol; 2012 Mar; 11(1):15-21. PubMed ID: 22427472
[TBL] [Abstract][Full Text] [Related]
4. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
[TBL] [Abstract][Full Text] [Related]
5. MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT.
Siemaszko J; Dratwa M; Szeremet A; Majcherek M; Czyż A; Sobczyk-Kruszelnicka M; Fidyk W; Solarska I; Nasiłowska-Adamska B; Skowrońska P; Bieniaszewska M; Tomaszewska A; Basak GW; Giebel S; Wróbel T; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2024 Jan; 72(1):. PubMed ID: 38847554
[TBL] [Abstract][Full Text] [Related]
6. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
7. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.
Martin PJ; Levine DM; Storer BE; Warren EH; Zheng X; Nelson SC; Smith AG; Mortensen BK; Hansen JA
Blood; 2017 Feb; 129(6):791-798. PubMed ID: 27872059
[TBL] [Abstract][Full Text] [Related]
9. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
10. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation.
Mullighan C; Heatley S; Doherty K; Szabo F; Grigg A; Hughes T; Schwarer A; Szer J; Tait B; To B; Bardy P
Transplantation; 2004 Feb; 77(4):587-96. PubMed ID: 15084940
[TBL] [Abstract][Full Text] [Related]
11. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
Kordelas L; Schwich E; Lindemann M; Heinemann FM; Buttkereit U; Horn PA; Beelen DW; Rebmann V
Front Immunol; 2019; 10():3027. PubMed ID: 31998310
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720
[TBL] [Abstract][Full Text] [Related]
13. Non-HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome?
Dickinson AM; Norden J
Int J Immunogenet; 2015 Aug; 42(4):229-38. PubMed ID: 26010044
[TBL] [Abstract][Full Text] [Related]
14. The major histocompatibility complex: a model for understanding graft-versus-host disease.
Petersdorf EW
Blood; 2013 Sep; 122(11):1863-72. PubMed ID: 23878143
[TBL] [Abstract][Full Text] [Related]
15. Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant.
Fraile P; Vazquez L; Caballero D; Garcia-Cosmes P; López L; San Miguel J; Tabernero JM
Eur J Haematol; 2013 Aug; 91(2):129-34. PubMed ID: 23710658
[TBL] [Abstract][Full Text] [Related]
16. [The clinical characteristics of polyserositis as main presentation of chronic graft-versus-host rejection disease after allogeneic hematopoietic stem cell transplantation].
Wang Q; Li Y; Qiu Z; Xu W; Sun Y; Wang L; Wang M; Liu W; Dong Y; Ou J; Wang W; Liang Z; Wang Q; Cen X; Ren H
Zhonghua Nei Ke Za Zhi; 2014 May; 53(5):394-7. PubMed ID: 25146408
[TBL] [Abstract][Full Text] [Related]
17. Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.
Martin PJ; Fan W; Storer BE; Levine DM; Zhao LP; Warren EH; Flowers ME; Lee SJ; Carpenter PA; Boeckh M; Hingorani S; Yan L; Hu Q; Preus L; Liu S; Spellman S; Zhu X; Pasquini M; McCarthy P; Stram D; Sheng X; Pooler L; Haiman CA; Sucheston-Campbell L; Hahn T; Hansen JA
Blood; 2016 Nov; 128(20):2450-2456. PubMed ID: 27758874
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
19. Chronic graft-versus-host disease in children and adolescents with thalassemia after hematopoietic stem cell transplantation.
Lertkovit O; Anurathapan U; Hongeng S; Thokanit NS; Pakakasama S
Int J Hematol; 2021 Apr; 113(4):556-565. PubMed ID: 33385291
[TBL] [Abstract][Full Text] [Related]
20. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
